Abstract
Withanolides are C-28 ergostane steroids known to demonstrate some very interesting therapeutic properties. Numerous withanolides have been isolated from a variety of different plant species and can be employed to treat various types of cancers. Withanolides are indeed capable of demonstrating excellent anticancer, anti-inflammatory, and neuroprotective activities. Additionally, libraries of prepared withaferin A analogs incorporating an acyl, sulphate, amide and aldehyde functionality have demonstrated the most potential response. It is of particular interest to note that an acetyl group at either C-4, C-19 or C-27 enhances the anticancer effects. Since the majority of natural withanolides reported in patents are classified as “Type-A”, it is our opinion that there should now be a focus on developing “Type-B” withanolides and an investigation into their various therapeutic applications. Moreover, very little real innovation in synthetic methodologies has been reported which opens up huge possibilities for novel synthetic methodologies to be developed for the production of larger libraries new withanolides and their analogs to incorporate chemical diversity. In addition, since withanolides have the capability to conjugate with other anticancer compounds, this should encourage scientists to prepare lead compounds in cancer drug discovery.
Keywords: Anticancer, drug discovery, ergostane steroids, in vitro, natural products, withanolide.
Recent Patents on Anti-Cancer Drug Discovery
Title:Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Volume: 13 Issue: 4
Author(s): Hidayat Hussain*, Rene Csuk, Ivan R. Green, Najeeb Ur Rehman, Ghulam Abbas and Wahid Hussain
Affiliation:
- Leibniz Institute of Plant Biochemistry, Department of Bioorganic Chemistry, Weinberg 3, D-06120 Halle (Salle),Germany
Keywords: Anticancer, drug discovery, ergostane steroids, in vitro, natural products, withanolide.
Abstract: Withanolides are C-28 ergostane steroids known to demonstrate some very interesting therapeutic properties. Numerous withanolides have been isolated from a variety of different plant species and can be employed to treat various types of cancers. Withanolides are indeed capable of demonstrating excellent anticancer, anti-inflammatory, and neuroprotective activities. Additionally, libraries of prepared withaferin A analogs incorporating an acyl, sulphate, amide and aldehyde functionality have demonstrated the most potential response. It is of particular interest to note that an acetyl group at either C-4, C-19 or C-27 enhances the anticancer effects. Since the majority of natural withanolides reported in patents are classified as “Type-A”, it is our opinion that there should now be a focus on developing “Type-B” withanolides and an investigation into their various therapeutic applications. Moreover, very little real innovation in synthetic methodologies has been reported which opens up huge possibilities for novel synthetic methodologies to be developed for the production of larger libraries new withanolides and their analogs to incorporate chemical diversity. In addition, since withanolides have the capability to conjugate with other anticancer compounds, this should encourage scientists to prepare lead compounds in cancer drug discovery.
Export Options
About this article
Cite this article as:
Hussain Hidayat *, Csuk Rene , Green R. Ivan , Ur Rehman Najeeb , Abbas Ghulam and Hussain Wahid , Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review, Recent Patents on Anti-Cancer Drug Discovery 2018; 13 (4) . https://dx.doi.org/10.2174/1574892813666180808154928
DOI https://dx.doi.org/10.2174/1574892813666180808154928 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Sugars and Sweeteners: Structure, Properties and In Silico Modeling
Current Medicinal Chemistry Recent Patents in Glycan-Based Cancer Biomarkers and Discovery Technologies
Recent Patents on Biomarkers Chirality - A New Era of Therapeutics
Mini-Reviews in Medicinal Chemistry Biological Imaging and Spectroscopy of pH
Current Organic Chemistry A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Current Drug Delivery Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry A2B Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology